Endothelin-1
Phase 1Small molecule
Endothelin-1 is one of 45 small molecule programs targeting Migraine. It is currently in Phase 1.
2
Indications
4
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
102 competitors in Migraine
#DrugCompanyPhaseTrials
1Avicel
SSanthera Pharmaceuticals
Phase 3
Effient
CCosette Pharmaceuticals, Inc.
Phase 3
Magnesium
SSpherium Biomed
Phase 3
Aspirin /d
TThe First Affiliated Hospital with Nanjing Medical University
Phase 3
Flunarizine
AAspartes Pharmaceuticals, Inc.
Phase 3
Tizanidine Hydrochloride
EElan Pharmaceuticals
Phase 3
Bayer Aspirin
BayerPreclinical
Cervidil
PfizerPreclinical
Cymbalta
Jazz PharmaceuticalsPreclinical
Adempas
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Vascular Function2 trials
Prenatal Aspirin and Postpartum Vascular Function
Recruiting·—·Phase 1·NCT05653973·60 enrolled
Nitric Oxide1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Endothelin-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- MMedical University of Vienna